Sofosbuvir Suppliers & Bulk Manufacturers
Available Forms: Film-coated Tablets
Available Strengths: 400 mg
Reference Brands: Sovaldi® (EU & US)
Category:
Hepatitis
Sofosbuvir 400 mg Tablets are oral direct-acting antivirals used in combination regimens for treating chronic Hepatitis C. Manufactured under EU-GMP and USFDA-compliant facilities, they are available for B2B supply, tenders, and licensing with full CTD dossiers and bioequivalence data to support registration in regulated markets.
Sofosbuvir is available in Film-coated Tablets
and strengths such as 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sofosbuvir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sofosbuvir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sofosbuvir Tablets are direct-acting antiviral agents (DAAs) used in combination therapy for the treatment of chronic Hepatitis C (HCV) across multiple genotypes. A nucleotide analog NS5B polymerase inhibitor, Sofosbuvir is available in 400 mg strength and forms the backbone of several pan-genotypic HCV regimens. Manufactured under EU-GMP or USFDA-approved facilities, Sofosbuvir is ideal for B2B licensing, tender supply, and distribution in regulated and semi-regulated markets. Offered with full CTD dossier, bioequivalence data, and stability studies, it supports rapid registration and commercialization in global markets. Available as a standalone API or FDF with partner molecules.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing